What is CHGCF stock price today?

CHGCF (Chugai Pharmaceutical Co. Ltd) stock is trading at $60.19 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CHGCF stock going up or down today?

CHGCF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CHGCF stock now?

The decision to buy CHGCF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CHGCF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CHGCF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CHGCF stock overvalued or undervalued?

CHGCF currently trades at a P/E ratio of 36.04, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if CHGCF is fairly priced.

What is CHGCF's P/E ratio?

CHGCF has a price-to-earnings (P/E) ratio of 36.04, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is CHGCF's market cap?

CHGCF (Chugai Pharmaceutical Co. Ltd) has a market capitalization of $99.06 billion, making it a mid-cap stock.

What is CHGCF's price to book ratio?

CHGCF trades at a price-to-book (P/B) ratio of 7.47, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CHGCF pay dividends?

Yes, CHGCF pays dividends with a current yield of 0.01%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is CHGCF's dividend yield?

CHGCF's dividend yield is 0.01%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is CHGCF stock a good long-term investment?

CHGCF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CHGCF's revenue growth rate?

CHGCF has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, CHGCF is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in CHGCF?

Key risks for CHGCF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CHGCF compare to its competitors?

Compare CHGCF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CHGCF's performance and positioning.

What is CHGCF's stock price target for 2026?

Our AI model provides price targets for CHGCF based on fundamental analysis: Bull case $78.25 (+30%), Base case $69.22 (+15%), Bear case $54.17 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CHGCF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CHGCF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CHGCF's next earnings report?

CHGCF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CHGCF - Chugai Pharmaceutical Co. Ltd

NYSE * Healthcare * Drug Manufacturers - General

$60.19

+$0.00 (+0.00%)

About Chugai Pharmaceutical Co. Ltd

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

CHGCF Key Statistics

Market Cap

$99.06B

P/E Ratio

36.04

P/B Ratio

7.47

EPS

$1.67

Dividend Yield

0.01%

Revenue Growth

+0.1%

Profit Margin

0.3%

Employees

7,872

How CHGCF Compares to Peers

CHGCF has the highest profit margins in Drug Manufacturers - General

CHGCF ranks 2nd in revenue growth vs peers

CHGCF is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CHGCF(This stock)	$99.06B	36.0	0%	0.3%	-
LLYEli Lilly	$829.71B	40.4	0%	0.3%	vs LLY
JNJJohnson &	$564.35B	21.2	0%	0.2%	vs JNJ
PFEPfizer Inc	$156.77B	20.0	-0%	0.1%	vs PFE
MRKMerck &	$294.39B	16.4	0%	0.3%	vs MRK
ABBVAbbvie Inc	$368.57B	87.6	0%	0.1%	vs ABBV

Chugai Pharmaceutical Co. Ltd Company Information

Headquarters: Nihonbashi Mitsui Tower, Chuo, Japan, 103-8324, undefined
Website: www.chugai-pharm.co.jp
Sector: Healthcare
Industry: Drug Manufacturers - General

About Chugai Pharmaceutical Co. Ltd

CHGCF Key Statistics

How CHGCF Compares to Peers

Chugai Pharmaceutical Co. Ltd Company Information

Upcoming Events for CHGCF